Company Description
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
The company offers ARIKAYCE for the treatment of refractory nontuberculous mycobacterial lung infections, as well as is in phase 3 clinical trial for the treatment of mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients.
It also devlops brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1(DPP1) that is in phase 3 clinical trial for the treatment of bronchiectasis; and in phase 2 clinical trial for the treatment of chronic rhinosinusitis without nasal polyps and hidradenitis suppurativa.
In addition, the company is developing treprostinil palmitil inhalation powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil, which is in phase 3 clinical trial for the treatment of pulmonary hypertension associated with interstitial lung disease; and phase 2 clinical trial for the treatment of pulmonary arterial hypertension.
Further, it develops gene therapy, a microdystrophin adeno-associated virus gene replacement therapy which is in phase 1 clinical trial for the treatment of Duchenne muscular dystrophy, as well as is in pre-clinical development for gene therapy, next generation DPP1 inhibitor, deimmunized therapeutic protein, and synthetic rescue.
The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
| Country | United States |
| Founded | 1988 |
| IPO Date | Jun 1, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1,271 |
| CEO | William Lewis |
Contact Details
Address: 700 US Highway 202/206 Bridgewater, New Jersey 08807 United States | |
| Phone | 908 977 9900 |
| Website | insmed.com |
Stock Details
| Ticker Symbol | INSM |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001104506 |
| CUSIP Number | 457669307 |
| ISIN Number | US4576693075 |
| Employer ID | 54-1972729 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| William H. Lewis J.D., M.B.A. | President, Chief Executive Officer and Chairman |
| Sara M. Bonstein M.B.A. | Chief Financial Officer |
| Roger Adsett M.B.A. | Chief Operating Officer |
| John Drayton Wise M.B.A. | Chief Commercial Officer |
| Dr. Martina Flammer M.B.A., M.D. | Chief Medical Officer |
| Brian K. Kaspar Ph.D. | Chief Scientific Officer |
| Bryan Dunn | Vice President of Investor Relations |
| Michael Alexander Smith J.D. | Chief Legal Officer and Corporate Secretary |
| Mandy Fahey | Vice President of Corporate Communications |
| S. Nicole Schaeffer M.B.A. | Chief People Strategy Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2025 | 8-K/A | [Amend] Current report |
| Apr 24, 2025 | 8-K | Current Report |
| Apr 17, 2025 | 8-K | Current Report |
| Apr 15, 2025 | 144 | Filing |
| Apr 4, 2025 | ARS | Filing |
| Apr 4, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 4, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 1, 2025 | 144 | Filing |
| Mar 17, 2025 | 144 | Filing |
| Mar 3, 2025 | 144 | Filing |